Abstracts tagged "Cardiovascular"

Abstract Number: 0128 • ACR Convergence 2021
Increased Risk of Major Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus After Non-Cardiac Surgery
Sebastian Bruera¹, Xiudong Lei², Brandon Blau¹, Hui Zhao², Anita Deswal², Jinoos Yazdany³, Sharon Giordano² and Maria Suarez-Almazor², ¹Baylor College of Medicine, Houston, TX, ²University of Texas MD Anderson Cancer Center, Houston, TX, ³University of California San Francisco, San Francisco, CA
Background/Purpose: The association between systemic lupus erythematosus (SLE) and cardiovascular disease has been well-studied. Cardiovascular disease is a risk factor for major adverse cardiac events…
Abstract Number: 0287 • ACR Convergence 2021
20 Years Follow-up of Cardiovascular Event Risk in Rheumatoid Arthritis Compared to Diabetes
Reinder Raadsen¹, Rabia Agca², Alexandre Voskuyl³, Maarten Boers⁴, Willem Lems⁵, Arno van Kuijk¹ and Michael Nurmohamed², ¹Reade, Amsterdam, Netherlands, ²Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁴Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁵VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis have an increased risk for developing cardiovascular diseases (CVD) compared to the general population, similar to the CVD risk in…
Abstract Number: 0863 • ACR Convergence 2021
Serum Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) and Cardiovascular Risk in Systemic Lupus Erythematosus: A Longitudinal Cohort Study
Chi Chiu Mok¹, Ling Yin Ho², Kar Li Chan³, Sau Mei TSE² and Chi Hung To⁴, ¹Tuen Mun Hospital, Hong Kong, China, ²Tuen Mun Hospital, Hong Kong, Hong Kong, ³Tuen Mun Hospital, Hong Kong, ⁴Pok Oi Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the predictive value of serum PCSK9 level on cardiovascular complications in Chinese patients with systemic lupus erythematosus (SLE).Methods: Consecutive patients who fulfilled…
Abstract Number: 1566 • ACR Convergence 2021
Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery
Rachael Flood, Colm Kirby, David Kane and Ronan Mullan, Tallaght University Hospital, Dublin, Ireland
Background/Purpose: Vascular endothelial cells line the entire circulatory system, these cells have very distinct and unique functions that are paramount to vascular biology. Hyperuricemia has…
Abstract Number: 0206 • ACR Convergence 2021
Hydroxycloroquine-Induced Atrioventricular Block in Inmune-Mediated Diseases. Single University Center Study of 293 Patients
Alba Herrero-Morant¹, Adrián Margarida-de Castro¹, Raquel Pérez-Barquín², Jon Zubiaur-Zamacola¹, Miguel Ángel gonzalez-Gay³ and Ricardo Blanco⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Hydroxychloroquine (HCQ) is an extensively used drug in immune-mediated diseases (IMID). Despite its general safety, HCQ can cause serious toxicity such as heart conduction…
Abstract Number: 0295 • ACR Convergence 2021
Weight History and Associations with Cardiovascular Risk in Patients with Rheumatoid Arthritis
Lydia Federico¹, Kaleb Michaud², Kristin Wipfler³, Gulsen Ozen⁴ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Bellevue, NE
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA), but traditional CVD risk factors may not accurately characterize risk. For…
Abstract Number: 0871 • ACR Convergence 2021
The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular Events in Patients with Systemic Lupus Erythematosus
Alejandra Londono Jimenez¹, Mohammad Hashim Mustehsan¹, Ana Valle², Jammie Law³, Shudan Wang², Maria Auxiliadora Salgado Guerrero⁴, David Briceno¹ and Anna Broder¹, ¹Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ³Montefiore Medical Center, Bronx, NY, ⁴Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Current guidelines recommend use of hydroxychloroquine (HCQ) at doses not exceeding 5mg/kg based solely on the increased risk of retinopathy at higher doses. This…
Abstract Number: 1573 • ACR Convergence 2021
Vascular Monosodium Urate Crystal Deposition in Gout: A Dual-energy CT and Microscopy Study of Cadaveric Donors
Nicola Dalbeth¹, Mariam Alhilali¹, Peter Riordan¹, Ravi Narang¹, Ashika Chhana¹, Sue McGlashan¹, Anthony Doyle¹ and MARIANO ANDRES², ¹University of Auckland, Auckland, New Zealand, ²Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain
Background/Purpose: Cardiovascular disease is a common comorbidity in people with gout. A hypothesized link between cardiovascular disease and gout is the deposition of monosodium urate…
Abstract Number: 0268 • ACR Convergence 2021
Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients
Dimitrios Pappas¹, George Reed², Kevin Kane², Jeffrey Curtis³ and Joel Kremer⁴, ¹Columbia University, New York, NY, ²University of Massachusetts, Worcester, MA, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Albany Medical College, Latham, NY
Background/Purpose: Cardiovascular disease (CVD) risk scores incorporating measures of inflammation such as the Reynolds risk score (RRS) may be appropriate to predict CVD risk in…
Abstract Number: 0305 • ACR Convergence 2021
Artificial Neural Networks Approaches to Predict Myocardial Fibrosis in Primary Sjögren Syndrome Patients Without Cardiac Symptoms
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Atsuma Nishiwaki¹, Isamu Yokoe¹, Haraoka Masaki³, Eichi Takaya³, Yousuke Nagasawa¹, Noboru Kitamura¹, Masami Takei¹ and Hideki Nakamura¹, ¹Nihon University School of Medicine, Itabashi, Japan, ²St. Marianna University School of Medicine, kowasaki, Japan, ³St. Marianna University School of Medicine, Kawaski, Japan
Background/Purpose: A recent meta-analysis of cardiovascular diseases demonstrated that the odds of heart failure (HF) was more than 2.54-fold higher in primary Sjögren syndrome (pSS)…
Abstract Number: 0879 • ACR Convergence 2021
Anti-dsDNA Antibodies Increase Systemic Lupus Erythematosus Cardiovascular Risk Impairing the Immune and Cardiovascular Systems
Carlos Pérez-Sánchez¹, Alejandra Patiño-Trives², Maria Angeles Aguirre³, Laura Perez-Sanchez³, Chary Lopez-Pedrera³, Maria Luque-Tevar², Maria del Carmen Ábalos-Aguilera³, Iván Arias de la Rosa⁴, Cristobal Román-Rodriguez³, Pedro Segui³, Mario Espinosa³, Pilar Font³, Nuria Barbarroja⁴, alejandro Escudero³, Eduardo Collantes-Estevez³, Jose Antonio Gonzalez-Reyes⁵, Jose Manuel Villalba⁵ and Chary lopez-pedrera³, ¹IMIBIC, Córdoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, ³IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁴University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁵Department of Cell Biology, Physiology and Immunology, University of Córdoba, Campus de Excelencia Internacional Agroalimentario, ceiA3, Cordoba, Spain
Background/Purpose: This study aimed to delineate the role of anti-dsDNA antibodies on the alterations observed in the gene profile and the activity of immune and…
Abstract Number: 1639 • ACR Convergence 2021
A Comparison of Cardiovascular Health Indicators in Children with Juvenile Idiopathic Arthritis Who Meet and Do Not Meet the Physical Activity Guidelines
Madelyn Byra¹, Nicole Proudfoot², Si Ru Chen¹, Maureen MacDonald³, Tania Cellucci⁴, Michelle Batthish⁵, Brian Timmons⁶ and Joyce Obeid⁶, ¹Child Health & Exercise Medicine Program, McMaster University, Hamilton, ON, Canada, ²Child Health & Exercise Medicine Program, McMaster University; Department of Kinesiology, McMaster University, Hamilton, ON, Canada, ³Department of Kinesiology, McMaster University, Hamilton, ON, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Child Health & Exercise Medicine Program, McMaster University; Department of Pediatrics, McMaster University, Hamilton, ON, Canada
Background/Purpose: Children with juvenile idiopathic arthritis (JIA) engage in less physical activity than their healthy peers. The Canadian 24-h Movement Guidelines recommend children take part…
Abstract Number: 0269 • ACR Convergence 2021
Autoantibodies and the Risk of Incident Cardiovascular Disease in US Veterans with Rheumatoid Arthritis
Tate Johnson¹, Michael Duryee², Carlos Hunter², Punyasha Roul², Yangyuna Yang², Jeremy Sokolove³, William Robinson⁴, Joshua Baker⁵, Geoffrey Thiele², Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Stanford University School of Medicine, Berwyn, PA, ⁴Stanford University, Stanford, CA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Autoantibodies are hypothesized as one of the RA specific factors contributing to a heightened risk of cardiovascular disease (CVD) in this population. However, prior…
Abstract Number: 0327 • ACR Convergence 2021
Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency
Caoilfhionn Connolly¹, Jessica Li², Daniel Goldman³, Andrea Fava², Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease. Cardiovascular disease is one of the leading causes of death in patients…
Abstract Number: 0910 • ACR Convergence 2021
The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
Jean Liew¹, S. Reza Jafarzadeh², Maureen Dubreuil³, Susan Heckbert⁴, Stephen Mooney⁴, Matthew Brown⁵, Mariko Ishimori⁶, John Reveille⁷, Michael Ward⁸, Michael Weisman⁹ and Lianne Gensler¹⁰, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine/ VA Boston, Boston, MA, ⁴University of Washington, Seattle, WA, ⁵King's College London, London, United Kingdom, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁸Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States, Rockville, MD, ⁹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) is associated with greater cardiovascular (CV) risk than in the general population. The impact of tumor necrosis factor inhibitors (TNFi) on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].